The purpose of this study is to evaluate the accuracy of Somnarus diagnostic technology for diagnosis of sleep apnea in human subjects. This includes evaluation of Somnarus technology in Obstructive Sleep Apnea (OSA) and Central Sleep Apnea (CSA), including Cheyne - Stokes respiration (CSR).

This is a multi- center, open label study to evaluate the accuracy of Somnarus device when compared with overnight polysomnographic measurements.

The study includes the following steps:

Screening the database or advertising among cardiologists, neurologists, pulmonologists and Ear Nose and Throat (ENT) specialists to identify potential subjects.

Initial visit, includes:

1. Consent discussion and signature
2. History, vital signs, and physical exam

Night study

a. A polysomnogram is conducted and, at the same time, a SomnaPatch device is used.

Additional visits If side effects occur, or if the data collection fails, or at the request of the sponsor to repeat the sleep study for further data collection and comparison.

Inclusion Criteria:

• Able to understand and sign the informed consent
• Able to comply with visits and follow ups included in this protocol
• Ages 20-85 years

Exclusion Criteria:

• An unstable medical condition, acute or chronic, that in the opinion of the investigator puts the subject at health risks related this trial or interferes with the clinical trial and data collection.
• Skin rash on the nose or on the maxillary area.
• A history of skin allergy to medical tape, and hypoallergenic tapes.
• A history of skin cancer on the nose or on the maxillary area.
• A history of the base of skull fractures, facial fractures

All adverse events were collected over the 1 night period

The two sets of data (PSG and Somnapatch) were scored independently. Therefore it was masked what set of data belonged to what individual.